Marshall Wace, LLP Rocket Pharmaceuticals, Inc. Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 10,100 shares of RCKT stock, worth $117,968. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,100
Previous 19,583
48.42%
Holding current value
$117,968
Previous $421,000
55.82%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding RCKT
# of Institutions
209Shares Held
93.2MCall Options Held
319KPut Options Held
70.3K-
Rtw Investments, LP New York, NY17.7MShares$207 Million5.21% of portfolio
-
Wellington Management Group LLP Boston, MA11.2MShares$131 Million0.04% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$72.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.54MShares$64.7 Million0.0% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.49MShares$52.5 Million0.39% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $884M
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...